ACTON, Mass. --(BUSINESS WIRE)--Nov. 7, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming investor conferences: The 2019 Stephens
ACTON, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months ended September
Insulet Further Demonstrating Commitment to Innovation and Patient Choice ACTON, Mass. --(BUSINESS WIRE)--Oct. 25, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today
ACTON, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the third quarter of 2019 on
ACTON, Mass. --(BUSINESS WIRE)--Sep. 23, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced it has received clearance from the U.S.
ACTON, Mass. --(BUSINESS WIRE)--Sep. 4, 2019-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), has priced a private placement of $700 million aggregate principal amount of
ACTON, Mass. --(BUSINESS WIRE)--Sep. 3, 2019-- Insulet Corporation (NASDAQ:PODD) ( Insulet or the Company), a leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced its intention to offer, subject to market and other conditions,
Mobile Apps Allow for Convenient and Discreet Remote Viewing of a User’s or Loved One’s Data ACTON, Mass. --(BUSINESS WIRE)--Aug. 9, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System
ACTON, Mass. --(BUSINESS WIRE)--Aug. 5, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial results for the three months ended June 30,
ACTON, Mass. --(BUSINESS WIRE)--Jul. 31, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that Jim Hollingshead , Ph.D., has been appointed to the
ACTON, Mass. --(BUSINESS WIRE)--Jul. 24, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at three upcoming investor conferences: The 39 th Annual
First of its Kind Website Intended to Educate and Mobilize the Diabetes Community to Drive Affordable Access ACTON, Mass. --(BUSINESS WIRE)--Jul. 17, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin
ACTON, Mass. --(BUSINESS WIRE)--Jun. 26, 2019-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the second quarter of 2019 on
Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79 th Scientific Sessions ACTON, Mass. --(BUSINESS WIRE)--Jun. 9, 2019-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its
No-Cost Personal Diabetes Manager, No Four Year Lock-in Period, and New User Interface Allow for Smooth Transition from Multiple Daily Injections (MDI) to Pod Therapy ACTON, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless
